Q-omics provides the consensus-scored GUSBP14 profile across patient tissues and cancer cell-line models. GUSBP14 expression is associated with patient survival in 15 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, GUSBP14 is differentially expressed in 8, with the highest sampling consensus in THCA. Additionally, GUSBP14 RNA expression shows 13,920 significant gene co-expression associations, with the highest sampling consensus in DLBC. Together, these results highlight KIRC, THCA, and DLBC as cancer lineages where GUSBP14 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for GUSBP14 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes GUSBP14 survival associations across molecular data types. GUSBP14 RNA expression shows survival associations in the most cancer types (15). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible GUSBP14 RNA expression–survival associations across cancer types. High GUSBP14 expression shows unfavorable associations in KIRC, ACC, THCA, UCEC and MESO, but favorable associations in LAML. The KIRC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p = .001). Together, the overview and detailed table identify KIRC as the clearest survival context for GUSBP14 RNA expression.
This table summarizes GUSBP14 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 8. The strongest signals are observed in THCA for RNA.
This table ranks reproducible tumor–normal expression differences for GUSBP14. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. GUSBP14 shows lower tumor expression in THCA, KIRP and KICH and higher tumor expression in STAD, BRCA and BLCA. The THCA box plot shows higher GUSBP14 RNA expression in normal versus tumor tissue (log2 FC = −0.310, t-test p < 0.001).
This table shows molecular features associated with GUSBP14 in patient tissues and cancer cell lines. In patient samples, GUSBP14 shows the broadest associations at the RNA and protein expression levels, with DLBC recurring as the lineage with the largest associated feature set. In cancer cell lines, GUSBP14 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in NCI60_ALL.
